Biopharma | June 05, 2026
Suven Life reports positive interim review for phase 3 Alzheimer’s therapy
Independent DSMB recommends continuation of Masupirdine without modifications as enrollment reaches 88% in global trial
Independent DSMB recommends continuation of Masupirdine without modifications as enrollment reaches 88% in global trial
The accrued data from the Phase 3 study suggest that the baseline characteristics of the enrolled patients are consistent with those observed in previous studies
The test is designed to help clinicians either rule in or rule out amyloid pathology in patients showing signs of cognitive decline
Lormalzi is the first and only once-monthly amyloid plaque-targeting therapy with clinical evidence
The company doses first patient in US study of Deraphan, as Dolby Ventures joins €53M Series B to support neuropsychiatric innovation
New minimally invasive biomarker test enables earlier diagnosis and improved clinical decision-making, aligned with global guidelines
Under the agreement, healthcare professionals in the country will gain access to C2N’s PrecivityAD2 blood test
Over 8.8?million Indians aged 60 and above currently live with dementia,
Blood tests measuring biomarkers such as p-tau217 are emerging as accurate, accessible alternatives
The company is excluding data from the affected sites to maintain the study's integrity
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
